TABLE II.

Multivariable logistic regression, factors predicting a duration of trifluridine/tipiracil therapy of 2 months or more^a

Factor	OR	95% CI	p Value
Age group
≤64 Years	1
≥65 Years	1.17	0.63 to 2.18	0.61
Sex
Women	1
Men	0.93	0.50 to 1.72	0.81
Geographic location
Prairie provincesb	1
British Columbia	0.46	0.15 to 1.40	0.17
Maritime provinces	0.49	0.12 to 2.03	0.32
Ontario	0.61	0.21 to 1.78	0.37
Quebec	0.71	0.25 to 2.00	0.52
KRAS status
Mutant	1
Wild-type	1.12	0.34 to 3.70	0.85
Fluorouracil–leucovorin
No	1
Yes	1.00	0.24 to 4.10	1.00
Bevacizumab
No	1
Yes	0.95	0.46 to 1.98	0.89
Capecitabine
No	1
Yes	0.54	0.22 to 1.33	0.18
CAPOX
No	1
Yes	2.70	0.63 to 11.56	0.18
Cetuximab
No	1
Yes	0.97	0.17 to 5.57	0.98
FOLFIRI
No	1
Yes	0.56	0.14 to 2.17	0.40
FOLFOX
No	1
Yes	3.02	0.92 to 9.87	0.07
Irinotecan
No	1
Yes	1.14	0.36 to 3.64	0.82
Panitumumab
No	1
Yes	0.88	0.26 to 3.02	0.84
Regorafenib
No	1
Yes	0.77	0.37 to 1.59	0.47

^aIncludes the 338 patients who discontinued therapy for any reason, who had available therapy start and stop dates, with non-missing covariate values.

^bAlberta, Saskatchewan, Manitoba.

^cNew Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island.

OR = odds ratio; CI = confidence interval; CAPOX = capecitabine–oxaliplatin; FOLFIRI = leucovorin–fluorouracil–irinotecan; FOLFOX = leucovorin–fluorouracil–oxaliplatin.